TrialESC heart failure2025

Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.

Marcin Ufnal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.